LncRNA AC007009.1与非小细胞肺癌临床分期相关性研究

doi:10.3969/j.issn.1671-7171.2021.02.031

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1161 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To study the correlation between LncRNA AC007009.1 and clinical stages of non-small cell lung cancer (NSCLC). 【Methods】 A total of 150 cases of NSCLC patients in our hospital from October 2015 to April 2019 were selected as the research objects. The cut-off value (5.23) of LncRNA AC007009.1 was taken from the median of LncRNA AC007009.1 level (5.24±2.05). The patients were divided into LncRNA AC007009.1 high expression group (n=93) and LncRNA AC007009.1 low expression group (n=57), The clinicopathological characteristics (age, gender, clinical stage, distant metastasis, smoking history, drinking history, tumor size) of the two groups were analyzed, and the difference information was included in the logistic regression analysis to analyze the risk factors of LncRNA AC007009.1 high expression, and to clarify the relationship between the pathological characteristics of NSCLC and LncRNA AC007009.1high expression, and to clarify the relationship between the pathological characteristics of NSCLC and lncRNA AC007009.1.【Results】 The patients with age≥60 years, distant metastasis, clinical stage Ⅲ or Ⅳ, smoking in high expression group were significantly more than those in low expression group (P<0.05); there was no significant difference in gender, history of alcohol abuse, tumor size between the two groups (P>0.05). Logistic regression analysis showed that age ≥ 60 years old, no distant metastasis, clinical stage Ⅲ or Ⅳ, smoking history were risk factors for LncRNA AC007009.1overexpression. 【Conclusion】 LncRNA AC007009.1 is closely related to the age, clinical stage, distant metastasis and smoking history of NSCLC. It can be used as an important indicator for early evaluation of NSCLC and has high clinical application value.

Key words： Carcinoma, Non-Small-Cell Lung/GE Carcinoma, Non-Small-Cell Lung/PA RNA Neoplasm Staging

Received: 26 August 2019

R730.26

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	REN Hong-min
	QIN Wen-jing

Cite this article:

REN Hong-min,QIN Wen-jing. Study on the Correlation between LncRNA AC007009.1 and Clinical Staging of Non-small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(2): 266-268.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.02.031 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I2/266

[1] 金发光. 我国肺癌早期筛查现状分析[J].医学与哲学, 2017, 38(1):14-18.
[2] 祝子明, 李凌云, 张年宝. 多西他赛联合顺铂方案在二线治疗晚期非小细胞肺癌中的应用价值[J].实用临床医药杂志, 2015, 19(11):123-125.
[3] 蒋姗彤, 李萍萍. 老年晚期非小细胞肺癌姑息治疗获益研究进展[J].中国肺癌杂志, 2015,18(7):462-468.
[4] 李文兵, 高德伟, 卢文宁, 等. 80岁以上老年非小细胞肺癌切除术后并发症及预后分析[J].解放军医学杂志, 2014, 39(10):823-825.
[5] 欧阳少波, 张鹏, 王军,等. 长链非编码RNA结肠癌相关转录子2在口腔鳞状细胞癌中的表达及临床意义[J].中华口腔医学杂志, 2016, 51(5):286-291.
[6] 杨培培, 宇龙, 孔旭, 等. 长链非编码RNA的异常表达在肿瘤中的作用[J].安徽医学, 2018, 39(11):1408-1411.
[7] 李敬华. MicroRNA及SNP在非小细胞肺癌易感性和早期诊断中的作用研究进展[J].中国肿瘤生物治疗杂志, 2016, 23(3):446-451.
[8] 赵闻. 金属硫蛋白与肺癌发病的研究进展[J].医学综述, 2014,20(11):1971-1972.
[9] 卢宏丽, 卢宏霞. 华蟾素联合化疗治疗中晚期非小细胞肺癌的临床疗效[J].中国药物与临床, 2015, 15(11):1609-1610.
[10] 李子付, 洪波, 刘建民. 长链非编码脱氧核糖核酸在脑血管疾病中的研究进展[J].中国脑血管病杂志, 2015,12(2):105-108.
[11] 潘金昌, 孟小丹, 龚朝辉. lncRNA作为竞争性内源RNA在非小细胞肺癌中的作用[J].生物化学与生物物理进展, 2018, 45(11):41-50.
[12] 李晓华, 田德兴, 唐微,等. lncRNA CRNDE在非小细胞肺癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2017, 24(8):889-894.
[13] 赵建, 刘建亮. miR-206及Bcl-2蛋白在非小细胞肺癌中的表达及意义[J].解剖科学进展, 2014,20(6):555-558.
[14] 曲安娜, 何平, 牛慧彦. 肺癌相关lncRNA调控肿瘤细胞EMT研究进展[J].齐鲁医学杂志, 2016,31(5):122-124.
[15] 黄时军, 杨军, 孙辉. 长链非编码RNA-H19促小细胞肺癌细胞株A549上皮-间质转化及侵袭[J].中国癌症杂志, 2015, 25(12):940-944.
[16] 程序, 余玲, 唐波, 等. lncRNA AC007009.1在非小细胞肺癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2017, 24(6):645-649.